Current knowledge on chronic hepatitis B therapy;Hépatite chronique virale B : Actualités thérapeutiques

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 4 SUPPL., 2001, Pages

  Zoulim, Fabien ^a,b   Werle, Bettina ^a  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CHRONIC HEPATITIS; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOTHERAPY; PATHOPHYSIOLOGY; TREATMENT PLANNING; VIRUS CORE; VIRUS RESISTANCE;

ADENINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; PHOSPHONIC ACIDS; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034913012     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (80)

1. Hepatitis B virus infection
2. Hepatitis B: The major etiology of hepatocellular carcinoma
3. The treatment of chronic viral hepatitis
4. Experimental systems for the study of hepadnavirus and hepatitis delta virus infections
5. Biochemical and genetic evidence for the hepatitis B virus replication strategy
6. Therapy of chronic hepatitis B virus infection: Inhibition of the viral polymerase and other antiviral strategies
7. Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy
8. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections
9. Viral clearance without destruction of infected cells during acute HBV infection
10. Hepatitis B virus transgenic mice: Insights into the virus and the disease
11. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
12. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
13. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
14. Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment
15. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B
16. Rapid detection of mutations in the promoter and the pre-core region of HBV genome: Correlation with viral persistence and disease activity
17. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum
18. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B
19. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-b-L-2′, 3′-dideoxy-3′-thyacytidine
20. Lamivudine as initial treatment for chronic hepatitis B in the United States
21. A one year trial of lamivudine for chronic hepatitis B
22. Lamivudine and IntronA combination treatment in patients with chronic hepatitis B infection
23. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
24. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy of chronic hepatitis B
25. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (Precore mutant) chronic hepatitis B
26. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
27. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
28. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR)
29. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
30. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
31. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
32. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
33. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
34. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
35. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance
36. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
37. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
38. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
39. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy
40. Early detection of viral resistance by determination of HBV polymerase mutations in patients treated by lamivudine for chronic hepatitis B
41. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy of chronic hepatitis B
42. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl) adenine, a potent anti-human immunodeficiency virus compound
43. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir
44. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
45. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection
46. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture
47. Lack of cross-resistance to PMEA for human hepatitis B DNA polymerases which express lamivudine resistance codons
48. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance
49. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo
50. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue
51. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: A randomized, double-blind, placebo-controlled trial
52. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection
53. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo controlled phase II studies
54. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
55. Viral dynamics in hepatitis B virus infection
56. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
57. Inhibitory effect of penciclovirtriphosphate on duck hepatitis B virus reverse transcription
58. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo
59. Efficacy of famciclovir in chronic hepatitis B: Results of a dose finding study
60. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
61. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
62. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir
63. A phase 2 multicenter-study of oral lobucavir for treatment of chronic hepatitis B
64. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
65. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
66. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-y1)cytosine in woodchuck hepatitis virus-infected woodchucks
67. Inhibitory effect of 2′-fluoro-5-methyl-b-L-arabinofuranosyl-uracyl on duck hepatitis B virus replication
68. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-b-L-arabinofuranosyl uracil
69. Inhibitory activity of new nucleoside analogs on wild type and YMDD mutants of the hepadnavirus reverse transcriptase
70. Characterization of the antiviral effect of 2′, 3′-dideoxy-2′, 3′- didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model
71. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: A possible way of circumventing «nonresponse to HBsAg»
72. Specific vaccine therapy in chronic hepatitis B infection
73. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus
74. DNA vaccines and viral hepatitis: Are we going around in circles
75. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein
76. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides
77. Gene therapy for chronic viral hepatitis: Ribozymes, antisense oligonucleotides, and dominant negative mutants
78. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents
79. Peptides that block hepatitis B virus assembly: Analysis by cryomicroscopy, mutagenesis and transfection
80. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking